drugset / Trial / NCT06934889
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.
Timeline
- Start
- 2025-04-07
- Primary completion
- 2028-04
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABBV-637 | Unknown | — | Intravenous |
| Subject | ERAS-801 | Small molecule | — | Oral |
| Subject | MIRZOTAMAB CLEZUTOCLAX | Unknown | — | Intravenous |
| Background | Temozolomide | Small molecule | — | — |